Stevanato Group to Report Fourth Quarter and Year End 2023 Financial Results on March 7, 2024
23 2월 2024 - 6:30AM
Business Wire
Stevanato Group S.p.A. (NYSE: STVN), a leading global provider
of drug containment, drug delivery, and diagnostic solutions to the
pharmaceutical, biotechnology, and life sciences industries,
announced today that it will issue financial results for the fourth
quarter and year end of 2023 on Thursday, March 7, 2024, at 6:30
a.m. (ET).
Conference call and webcast: The Company will host a
conference call and webcast at 8:30 a.m. (ET) on Thursday, March 7,
2024, to discuss financial results. During the call, management
will refer to a slide presentation which will be available on the
morning of the call on the “Financial Results” page under the
Company's Investor Relations section of its website.
Pre-registration: Participants who pre-register will be
given a conference passcode and unique PIN to gain immediate access
to the call and bypass the live operator. We encourage participants
to pre-register for the conference call using the following link:
STVN conference call pre-registration.
Webcast: A live, listen-only webcast of the call will be
available at the following link: STVN webcast.
Dial in: Those who are unable to pre-register may
dial in by calling:
Italy: +39 02 802 09 11 United Kingdom: +44 1
212 818004 United States: +1 718 705 8796 United States Toll Free:
+1 855 265 6958
Questions during the call: Participants who wish to ask
questions during the call should use the HD webphone link:
https://hditalia.choruscall.com/?$Y2FsbHR5cGU9MiZpbmZvPWNvbXBhbnk=.
Replay:
The webcast will be archived for three months on the Company’s
Investor Relations section of its website.
About Stevanato Group
Founded in 1949, Stevanato Group is a leading global provider of
drug containment, drug delivery and diagnostic solutions to the
pharmaceutical, biotechnology and life sciences industries.
Stevanato Group delivers an integrated, end-to-end portfolio of
products, processes and services that address customer needs across
the entire drug life cycle at each of the development, clinical and
commercial stages. Stevanato Group’s core capabilities in
scientific research and development, its commitment to technical
innovation and its engineering excellence are central to its
ability to offer value added solutions to clients. For more
information, please visit www.stevanatogroup.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240222927797/en/
Investor Relations Lisa Miles
lisa.miles@stevanatogroup.com
Media media@stevanatogroup.com
Stevanato (NYSE:STVN)
과거 데이터 주식 차트
부터 10월(10) 2024 으로 11월(11) 2024
Stevanato (NYSE:STVN)
과거 데이터 주식 차트
부터 11월(11) 2023 으로 11월(11) 2024